Nuri Clinic offers access to advanced peptide therapy and holistic health services, including live support from medical professionals.

Nuri Clinic

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

George Rathmann

Amgen Inc.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

E. R. Squibb

John Ripley Myers

William McLaren Bristol

Bristol-Myers Squibb Company

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Metric
Company Name	Nuri Clinic	Amgen Inc.	Bristol-Myers Squibb Company	Crinetics Pharmaceuticals, Inc.
Symbol		AMGN	BMY	CRNX
MSH ID	COM:NURICLINIC	COM:AMGEN	COM:BMS	COM:CRINETICS
Market	PRIVATE	STOCKS	STOCKS	STOCKS
Sector	Healthcare & Health Services	Healthcare	Healthcare	Healthcare
Industry	Health and Wellness	Drug Manufacturers - General	Drug Manufacturers - General	Biotechnology
Country	US	US	US	US
Stage
Employee Count		26.70K	34.10K	290
Website	nuriclinic.com	amgen.com	bms.com	crinetics.com
LinkedIn		amgen		crinetics-pharmaceuticals
Founders

Metric
Market Cap	172.56B	83.35B	4.01B
Enterprise Value
Monthly Web Traffic	1.00M		29.06K
Web Traffic Growth	-0.02		-0.40
Valuation
Raised Capital	28.50B		500M

Metric
Revenue	28.19B	45.01B	4.01M
Revenue (LTM)
Revenue (NTM)
Gross Profit	19.74B	34.31B	2.92M
EBITDA	7.90B	19.18B	-221.51M
Operating Income	7.90B	17.24B	-222.61M
Net Income	6.72B	8.03B	-214.53M
EPS	12.56	3.88	-3.69
Diluted EPS	12.49	3.86	-3.69
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.70	0.76	0.67
Operating Profit Margin	0.32	0.31	-55.47
EBITDA Margin	0.28	0.43	-55.20
Net Profit Margin	0.24	0.18	-52.96
Return on Equity	1.03	0.26	2.98
Return on Assets	0.07	0.08	-0.24
Return on Capital Employed	0.12	0.19	-0.27

COM:NURICLINIC

Nuri Clinic

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	22.81	11.94	-10.94
P/B Ratio	22.55	3.41	-3.59
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	6.11	2.36	3.84K
EV Multiple	12.57	4.18	-14.83

Metric
Days Sales Outstanding	83.59	127.10
Days Payables Outstanding	69.95	97.40
Days Inventory Outstanding	411.08	98.52
Operating Cycle	513.92	214.66	1.75K
Cash Conversion Cycle	445.24	103.41	-493.80
Asset Turnover	0.34	0.49	0.01

Metric
Operating Cash Flow	8.47B	13.86B	-166.31M
Free Cash Flow	7.36B	12.65B	-171.00M
Cash Flow to Debt	0.13	0.33	-3.22
Operating Cash Flow/Sales	0.30	0.31	-41.44
Free Cash Flow Yield	0.06	0.12	-0.05

Metric
Cash & Equivalents	10.94B	11.46B	54.90M
Accounts Receivable	-1.01B	-995M	14.65M
Inventory	9.52B	2.66B
Goodwill	18.63B	21.17B
Debt to Capitalization	0.93	0.78	0.09
Debt to Assets	0.67	0.43	0.08
Current Ratio	2.86	1.18	14.23
Quick Ratio	1.62	1.24	17.72

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.03	0.01	5.55
R&D to Revenue	0.17	0.21	33.87
SG&A to Revenue			11.07